NovartisNVS announced that the European Commission (EC) has approved Revolade for the treatment of pediatric patients (aged 1 year and above) suffering from chronic immune (idiopathic) ...
Revolade is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results